Probably not a 'be all end all', but why not something simple and practical, like a short-term memory test? Perhaps, something that could be administered as on a smart-phone app. The power here could be the development of a baseline and observe the changes longitudinally compared to placebo and even general population.
Maybe this is already being done and I'm behind on the literature.
Thats a great idea-- but did not pan out in practice (see Alto Neuroscience's very recent trial using a memory biomarker to try to subset patients for greater benefit):
Wow, great link! Based on a quick read, it's not clear to me that there is a problem with memory memory tests vs the drug really just lacking phenotypic impact. It looks like it failed to meet its primary endpoint in general. Perhaps I'm missing something.
Agreed, the test in itself is not the issue, it is how to use it, and how to link it to a practical usecase. Wonder what could be the best application in a trial. Different indication, different endpoint, no patient stratification, etc.?
Probably not a 'be all end all', but why not something simple and practical, like a short-term memory test? Perhaps, something that could be administered as on a smart-phone app. The power here could be the development of a baseline and observe the changes longitudinally compared to placebo and even general population.
Maybe this is already being done and I'm behind on the literature.
Thats a great idea-- but did not pan out in practice (see Alto Neuroscience's very recent trial using a memory biomarker to try to subset patients for greater benefit):
https://investors.altoneuroscience.com/news/news-details/2024/Alto-Neuroscience-Reports-Topline-Results-from-a-Phase-2b-Trial-Evaluating-ALTO-100-as-a-Treatment-for-Major-Depressive-Disorder/default.aspx
Wow, great link! Based on a quick read, it's not clear to me that there is a problem with memory memory tests vs the drug really just lacking phenotypic impact. It looks like it failed to meet its primary endpoint in general. Perhaps I'm missing something.
Agreed, the test in itself is not the issue, it is how to use it, and how to link it to a practical usecase. Wonder what could be the best application in a trial. Different indication, different endpoint, no patient stratification, etc.?